Kornimate/medical-research-clean huggingface dataset:
bevacizumab neoadjuvant therapy for new high-grade gliomas in the brain

Conditions: Brain Glioma

Summary: glioblastoma (gbm) usually grows in a diffuse fashion and infiltrates the surrounding brain. the inability to completely excise the tumor often leads to tumor recurrence within a few months of the initial surgery, which ultimately results in the death of the gbm patient.gbm histologically appears to be a tumor of vascular origin characterized by necrosis and microvascular proliferation, and neoangiogenesis is a key factor in the growth and poor prognosis of gbm. bevacizumab can inhibit the biological effects of vegf, including the permeability and proliferation of blood vessels, as well as the migration and survival of endothelial cells, so as to inhibit tumor angiogenesis, growth and metastasis. the aim of this study is to evaluate the efficacy and safety of bevacizumab in the preoperative adjuvant treatment of patients with new-onset high-grade gliomas.

glioblastoma (gbm) usually grows in a diffuse fashion and infiltrates the surrounding brain. the inability to completely excise the tumor often leads to tumor recurrence within a few months of the initial surgery, which ultimately results in the death of the gbm patient.gbm histologically appears to be a tumor of vascular origin characterized by necrosis and microvascular proliferation, and neoangiogenesis is a key factor in the growth and poor prognosis of gbm. therefore, inhibition of neoangiogenesis has received increasing attention from researchers as an important potential therapeutic target for gbm. bevacizumab specifically binds to vegf (mainly to vegf-a), attenuates or prevents vegf from binding to vegfr-1 and vegfr-2 on the surface of vascular endothelial cells, and blocks vegfr-mediated downstream signaling pathways, inhibiting their biological activities, reducing tumor neovascularization and limiting tumor growth. based on this background, the aim of this study was to evaluate the efficacy and safety of bevacizumab in the preoperative adjuvant treatment of patients with new-onset high-grade gliomas.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * male or female. * imaging diagnosis of high-grade glioma. * kps score ≥60. exclusion criteria: * prior treatment with anti-angiogenic targeted drugs; * comorbid serious cardiac, pulmonary, hepatic, or renal disease; * history of an arterial/venous thrombotic event within 6 months prior to screening; * combination of infectious diseases such as tuberculosis and viral hepatitis; * comorbid infectious diseases such as tuberculosis, viral hepatitis, uncontrolled high blood pressure, bleeding disorders, and long-standing unhealed wounds or incompletely healed fractures; * patients with a history of psychotropic substance abuse that cannot be stopped or patients with mental disorders; * abnormal coagulation function, with bleeding tendency * patients who, in the opinion of the investigator, are not suitable for inclusion in the study (e.g., pregnant and lactating women).
three arm trial of immune effects of echinacea

Conditions: Upper Respiratory Tract Infections

Summary: the goal of this study is to determine if either of two, commercially available, echinacea purpurea products stimulate the immune system. for the study, 60 healthy adults will be randomized to receive one of the two echinacea purpurea products or placebo for 10 days. blood will be drawn to assess immune markers just before beginning the study medication, during the 10 day course of medication and after completing the course of medication. it is postulated that adults receiving either of the echinacea products will have evidence of immune stimulation and those receiving placebo will not.


Eligibility criteria:
inclusion criteria: * healthy adult (based on a screening health questionnaire) * speaks and reads english. * if female of child-bearing potential, willing to use contraception to prevent pregnancy during the study. * no use of any medication (other than multivitamins, essential fatty acids, oral contraceptives and probiotics) for 2 weeks prior to first dose of study. * willing to abstain from ingesting edible mushrooms for 2 weeks prior and throughout study. * willing to eat less than 2 garlic cloves per day for 2 weeks prior and during the study period exclusion criteria: * pregnancy or currently breastfeeding. * history of autoimmune disease or immune disorders. * history of asthma. * history of allergic rhinitis. * history of physician diagnosed eczema, psoriasis or other skin condition that could mask an echinacea-induced rash. * known allergic reaction to echinacea or related species, specifically ragweed (ambrosia), chamomile (matricaria), goldenrod (solidago), and sunflower (helianthus). * known allergic reaction to xylitol sweetener, glycerine, citric acid, or citrus fruits

Keywords: echinacea immune modulation prevention
psychometric properties and cross-cultural adaptation of the turkish version of physcian attitudes toward cardiac rehabilitation and referral scale-revised (pacrr-r)

Conditions: Physician's Role

Summary: research has reported that the reasons for low implementation of cr are multifactorial at the health system, physician and patient levels. it has also been found that patients are more likely to initiate cr if physicians strongly and positively promote the importance of cr participation. unfortunately, there are insufficient and ineffective data on cr, referral to cr and both clinical and cost-effectiveness outcomes of cr in turkey. in this context, it is important to examine more objectively from the perspective of physicians who play a key role in referring patients to cr. however, in our country, there is no relatively objective measurement tool to evaluate physicians' attitudes towards cr. therefore, this study aims to adapt the original "physician attitudes towards cardiac rehabilitation and referral scale-revised (pacrr-r)" into turkish and to examine its psychometric properties.


Eligibility criteria:
inclusion criteria: * to be a physician, * providing active service in patient diagnosis and treatment exclusion criteria: * not providing active service in patient diagnosis and treatment despite being a physician (administrative position, etc.).
upper limb mirror therapy with bilateral transcutaneous electrical nerve stimulation to improve upper limb functions in patients with stroke

Conditions: Stroke

Summary: this study compare the effectiveness of 2 rehabilitation programmes that use (1) mt with bilateral tens (bi-tens), (2) sham-mt with bi-tens (bi-tens), respectively, in addition to conventional rehabilitation of standardized upper limb training, in improving upper limb motor functions, activities of daily living, community integration, and quality of life in patients with stroke.

the principal aim of the proposed study will be to demonstrate whether mt with bi-tens is more effective than sham-mt with bi-tens in improving upper limb motor functions, activities of daily living, community integration and quality of life in patients with stroke. the null hypothesis will be that mt with bi-tens is not significantly different from sham-mt with bi-tens in improving upper limb motor functions, activities of daily living, community integration, and quality of life in patients with stroke.

Eligibility criteria:
inclusion criteria: 1. have been diagnosed with ischemic brain injury or intracerebral hemorrhage by mri or computed tomography within three weeks to 10 years after the first onset of stroke; 2. have volitional control of the non-paretic arm, and at least minimal antigravity movement in the shoulder of the paretic arm; 3. have at least 5 degrees in wrist extension of the paretic arm in the antigravity position 4. are able to score \> 6 of 10 of abbreviated mental test; 5. are able to follow instruction and give informed consent of the study. exclusion criteria: 1. have any additional medical, cardiovascular and orthopedic condition that would hinder the proper assessment and treatment; 2. use cardiac pacemakers; 3. have receptive dysphasia; 4. have a significant upper limb peripheral neuropathy (e.g., diabetic polyneuropathy); 5. have severe shoulder, elbow, wrist or finger contractures that would preclude a passive range of motions of the arm; 6. have skin allergy that would prevent electrical stimulation; 7. are involved in drug studies or other clinical trials.
identification of the cranberry juice compounds that prevent urinary tract infections

Conditions: Urinary Tract Infections

Summary: the purpose of this study is to identify the substances in cranberry juice that make it effective in reducing urinary tract infections (utis) in women.

urinary tract infections (utis) are a significant health issue, with one fourth of all women experiencing symptoms during their lifetimes. cranberry juice has been shown to reduce the incidence of utis by preventing bacteria from adhering to the bladder. however, the compounds that direct this activity have not been identified. this study will identify and examine uti-reducing compounds in cranberry juice. participants in this study will drink a specified amount of water following an overnight fast. their urine will be collected 1 to 3 hours after the water is consumed. several days later, the women will be provided with cranberry juice to replace the water in the regimen. urine samples will be analyzed for compounds that have antibacterial or antiadhesion activity against the bacteria that cause utis.

Eligibility criteria:
inclusion criteria: * good overall health exclusion criteria: * history of urinary tract infections * use of cranberry products or antibiotics within 1 week of study start * current use of any other medication * hypertension * diabetes * pregnancy

Keywords: vaccinium macrocarpon
clinical trial of kanglaite injection (klti) in advanced non-small cell lung cancer (nsclc)

Conditions: NSCLC

Summary: the purpose of this study is to evaluate the efficacy and safety of kanglaite injection for advanced non-small cell lung cancer(nsclc).

this study include a multicenter, randomized, controlled post-market clinical trial.the randomized clinical trial will enroll approximately 334 patients. participants will be randomly divided into experimental (n=167) and control groups (n=167).patients in the experimental group will receive kanglaite injection combination with first-line chemotherapy based on nccn guidelines (2019.v3). patients in the control group will receive first-line chemotherapy based on nccn guidelines (2019.v3).the primary endpoint is pfs(progression free survival).the research protocol was approved by the relevant ethics committees, and the study was conducted according to the declaration of helsinki and good clinical practice guidelines. patients gave written informed consent to participate in the trial.

Eligibility criteria:
inclusion criteria: * a histological or cytological confirmed diagnosis of stage iii-iv nsclc, with no history of anticancer treatment including chemotherapy; * male or female aged 18-75years; * eastern cooperative oncology group (ecog) performance score 0-2; * life expectancy of at least 3 months; * at least one radiographically measurable lesion per recist 1.1; * willing to join the clinic trail and sign informed consent; * able to comply with scheduled visits and treatments. exclusion criteria: * presence of cerebral metastases; * confirmed positive for expression of expression of epidermal growth factor receptor (egfr), activin receptor-like kinase (alk), c-ros oncogene 1 (ros1) mutation, or programmed death-ligand 1 (pd-l1)(tumor proportion score \[tps≥ 50%\] in a genetic test; * participants with malignant pleural effusion underwent intrapleural injection chemotherapy; * current undergoing or preparing for treatment with target therapy; * current undergoing or preparing for radiotherapy to the thorax; * current undergoing or preparing treatment with tumor immunotherapy; * currently undergoing lipid-decreasing treament; * pregnant or breastfeeding woman; * fertile patients who are unwilling or unable to take effective contraceptive measures during the research period until 6 months after the study end later; * a history of mental disorders； * severe and uncontrolled organic lesion or infection, including but not limited to cardiopulmonary failure and renal failure，which lead to poor tolerance of chemotherapy; * participated in other clinical trials of small molecule research drugs within 28 days prior to enrollment, or participated in other clinical trials of large molecule research drugs within 3 months before enrollment; * known allergy or intolerance to study medications; * considered to be otherwise unsuitable for the clinical study by researchers.

Keywords: advanced non-small cell lung cancer kanglaite injection chinese herbal medicine randomized controlled trial progression-free survival
new technologies as a tool for health promotion in schoolchildren of compulsory secondary education

Conditions: Adolescent Behavior; Physical Activity; New Technologies

Summary: the rapid development of new technologies could be one of the causes that has favored changes in the lifestyle habits of young people. research carried out to date shows that new technologies could be useful in increasing levels of physical activity and motivation to practice sports. however, these studies have major limitations that make it difficult to generalize the results. the objectives of the present project are: 1) to determine the influence of the use of new technologies on the levels of sports practice and the physical and psychological health of adolescents; 2) to analyze the effects of a physical-sports activity program that integrates new technologies through mobile applications related to physical exercise on the level of physical activity and the physical and psychological health of adolescents; and 3) to analyze the adherence that this type of program generates in the medium term in adolescents as a function of age and gender. the project will be divided into two phases. in the first phase, 500 students from the centers of compulsory secondary education will be included, who will undergo physical tests, questionnaires related to sports practice and physical and psychological health, and an anthropometric assessment. in the second phase, an intervention will be carried out with four experimental groups and a control group. the four experimental groups will use different technological applications outside school hours for 12 weeks. participants will keep a weekly record of physical activity and pre-, post and re-test measurements will be taken to evaluate the efficacy of the sports technology applications in increasing and maintaining physical activity.


Eligibility criteria:
inclusion criteria: * be a student of compulsory secondary education * not present any disease or surgical operation that would prevent the performance of the physical tests or the follow-up of the established intervention. * complete the questionnaires provided and carry out the established tests in their entirety * have access to any mobile device that allows access to the technological sports applications used in the intervention. exclusion criteria: * failure to complete the questionnaires provided and/or to take the prescribed tests in their entirety * failure to complete scheduled intervention activities.

Keywords: adolescents physical activity psychology new technologies
tdcs for fatigue in sjogren's syndrome

Conditions: Sjogren's Syndrome

Summary: sjogren's syndrome (ss) is an autoimune disease of unknown etiology characterized by lymphocytic infiltration of the exocrine glands and other organs. patients usually presents with xerophthalmia, xerostomia, fatigue and other symptoms. fatigue has often been reported as the biggest problem and the most difficult symptom patients have to deal with. fatigue management in pss is difficult. however, in other diseases such as parkinson disease, post-polio syndrome and multiple sclerosis the use of transcranial direct current stimulation (tdcs) has recently been studied and has shown effectiveness. the overarching objective of this study is to examine the effect of a tdcs protocol in patients with pss.


Eligibility criteria:
inclusion criteria: * women * age between 18 and 65 years old; * diagnosis of primary sjogren's syndrome according to american-european criteria; * stable pharmacological therapy for at least 3 months; * complaints of fatigue as assessed by fatigue severity scale (fss\>5). * complaints of fatigue for more than 3 months. exclusion criteria: * heart, coronary, respiratory, renal, or hepatic uncompensated insufficiencies; * uncompensated systemic arterial hypertension; * unable to answer the questionnaires. * severe depression (with a score \> 30 in the beck depression inventory) * history of epilepsy or syncope * implanted brain metallic devices * established cognitive impairment * traumatic brain injury with residual neurological deficits

Keywords: sjogren's syndrome fatigue tdcs
pediatric nevirapine resistance study

Conditions: AIDS; HIV Infections

Summary: this study is designed to test if a sequential protease-inhibitor (pi) - / nevirapine (nvp) -based regimen is effective for the treatment of hiv-infected children when previous nvp exposure has occurred as part of programs to prevent mother-to-child transmission (pmtct).

the wide use of nvp in pmtct-prophylaxis may result in resistance to nnrti and concomitantly limits the use of these drugs for the treatment of hiv-infected children. to avoid restricting treatment options for children, it is desirable to preserve nvp for both pmtct and first line treatment. this study will therefore test whether resistance-caused treatment failures of hiv-infected and previously nvp-exposed children can be avoided if the nvp treatment is preceded by an initial pi-based regimen. comparison: hiv-infected children less than 24 months of age, exposed to any pmtct regimen that included nvp and who achieve and maintain viral suppression for at least 3 months with a pi-based regimen will be randomized to one of the two groups: (1) to continue on pi-containing regimen or (2) to be switched off the pi-containing regimen onto the nvp-containing regimen. the study outcome will be proportions in the two groups who have complete virologic suppression at 6 months after randomization.

Eligibility criteria:
inclusion criteria: * nvp-exposure as part of pmtct-prophylaxis around delivery * hiv-positive * eligible for treatment * plans to stay in the area for the next 6 months exclusion criteria: * already on anti-retroviral treatment * history of toxicity to perinatal nvp * grade 3 or greater elevation of liver function tests * being treated for a severe acute opportunistic infection or tumor

Keywords: non-nucleoside reverse transcriptase inhibitor drug resistance hiv seronegativity treatment naive
to assess the level of adherence of subjects receiving saizen® via easypod™ in mexico

Conditions: Growth Disorders

Summary: this is a mexican, multicentre, observational study to evaluate adherence and long term outcomes of therapy in paediatric subjects using easypod™ electromechanical device for growth hormone treatment to assess the level of adherence of subject receiving saizen® via easypod™.

subjects will be enrolled in a multicenter longitudinal observational study. parents and patients will provide their informed consent to upload their data for population-based analyses and optionally to adhere to a patient adherence support program "aumenta" designed to improve their adherence and, ultimately, clinical outcomes. adherence data will be primarily derived from the easypod™ device combined with physician data entry of outcome measures. data will be collected retrospectively and prospectively. this will allow the establishment of adherence profiles and explore the hypothesis that patient adherence support programs improve adherence and subsequent clinical outcomes. collected data will be also analyzed in a multinational pooled analysis of comparable national studies. primary objective: -to assess the level of adherence of subjects receiving saizen® via easypod™ secondary objectives: * to describe the impact of adherence on clinical outcomes for subject receiving saizen® via easypod™ * to identify adherence subject profiling * to asses the impact of adherence on igf1 (i.e. above, below or within normal ranges) * to assess/describe the impact of mexico patient support program "aumenta"

Eligibility criteria:
inclusion criteria: * administered growth hormone via the easypod™ electromechanical device according to local prescribing information * over the age of \> 2 years * under \< 18 years of age, or over 18 without fusion of growth plates * parents' or guardian's written informed consent, given before entering data into the observational study, with the understanding that the subject or parents/guardian may withdraw consent at any time without prejudice to future medical care. if the child is old (over 18 without fusion of growth plates) or able to give written informed consent, a separate assent form will be given * patient signed informed consent if has 7-17 years old * patient signed informed consent if has 18 years old exclusion criteria: * subjects taking growth hormone in whom growth plates have fused (i.e. for taking growth hormone for it's metabolic effects) * contra-indications to saizen® as defined in the local prescribing information * use of an investigational drug or participation in another interventional clinical study

Keywords: growth disorders saizen easypod growth hormone pediatric subject
long term predictors of acute myocardial infarction in patients with coronary revascularization

Conditions: Acute Myocardial Infarction; Revascularization

Summary: worldwide, ischemic heart disease is the single most common fatal disease. one of the most common causes of acute myocardial infarction is represented by obesity. numerous cardio metabolic variables play a key role in incidence of adverse cardiovascular outcomes. the purpose of this research was to investigate the factors allowing to acute coronary syndrome, related to the metabolic status, to help guide each patient toward early preventing behaviors.


Eligibility criteria:
inclusion criteria: * patients met the criteria for acute coronary syndrome (acs) as defined by the joint european society of cardiology/american college of cardiology committee. * patients underwent immediate coronary revascularization (primary pci) for st-elevation myocardial infarction (stemi). * patients underwent coronary revascularization (early pci) within 24 hours for non-st-elevation myocardial infarction (nstemi). * patients underwent diagnostic coronary angiography following coronary artery bypass graft surgery (cabg). exclusion criteria: * known coronary artery disease or previous acs. * pci following cabg. * cardiogenic shock. * atrial fibrillation. * peripheral artery disease. * severe cardiac valve disease. * prosthetic aorta.
capillary lactate and transfusion needs

Conditions: Trauma

Summary: 13% of injured normotensive patients arriving in emergency unit need mass blood-transfusion of six or more units of packed red blood cells. it is currently difficult to predict the need for such a mass blood-transfusion. indeed hemoglobin point of care testing (hemocue) and blood pressure can be normal during the first hours despite intensive bleeding. it's well known that blood or arterial lactate measures correlate with trauma severity but these measures are not available in a pre-hospital setting. the investigators want to test whether capillary lactate measures also correlate with trauma severity and can therefore predicts earlier transfusion needs.


Eligibility criteria:
inclusion criteria: * adult admitted in vital emergency unit * severe trauma * normotensive (systolic blood pressure \>90mmhg) * patient subjected to capillary haemoglobin and glucose measurements * patient beneficiary of social security exclusion criteria: * pregnant woman * liver deficiency * pre-hospital transfusion * hypothermia below 35°c * protected persons according to the law * nor epinephrine \> 0.1gamma/kg/min

Keywords: adults admitted in vital emergency unit